UBS Global Biopharma Conference 2026
Logotype for Denali Therapeutics Inc

Denali Therapeutics (DNLI) UBS Global Biopharma Conference 2026 summary

Event summary combining transcript, slides, and related documents.

Logotype for Denali Therapeutics Inc

UBS Global Biopharma Conference 2026 summary

17 Nov, 2026

AVLAYAH launch

  • AVLAYAH’s launch generated close to $18M last quarter, versus prior guidance of $10M-$12M; faster commercial and Medicaid access and EAP patient transitions drove the upside.

  • Guidance for the coming quarter is $30M-$32M; the majority of patients are switches from Elaprase, and roughly 95% of MPS II patients had already received enzyme replacement therapy.

  • The U.S. Hunter syndrome population is 500, with 375 eligible under the FDA label; management expects to become the Hunter market leader next year and anticipates strong growth in 2026-2027.

  • Management described AVLAYAH as validating the TransportVehicle platform, which it plans to apply to enzyme replacement, Alzheimer’s and other programs.

Hunter and Sanfilippo

  • COMPASS enrolls 56 patients in two cohorts; co-primary endpoints are CSF heparan sulfate and a Vineland composite, with Bayley and systemic measures among secondary endpoints.

  • Cohort A patients are expected to reach the two-year endpoint by the end of next year, with data anticipated in 2028; COMPASS is intended to support label expansion and filings in additional international markets.

  • Sanfilippo data from the first eight patients showed robust heparan sulfate reduction and normalization of liver and spleen measures; 49-week study follow-up ended in September, with pivotal data planned for WORLDSymposium in February.

  • ZAFY is being manufactured at the U.S. facility; readiness for inspection, launch preparation and manufacturing cost optimization are current priorities.

Alzheimer’s programs

  • MAPT phase I readouts are expected in 2027; initial assessment will focus on CSF tau reduction and its distribution, with tau PET data taking longer and potentially requiring one to two years.

  • Management said MAPT’s Oligonucleotide TransportVehicle aims to deliver more even CNS distribution than intrathecal dosing; the phase I-B goal is to select a dose achieving target knockdown.

  • A-beta data are also targeted for 2027, including plaque reduction in patients after healthy-volunteer testing; the program aims to enable subcutaneous administration.

  • Management cited $3B-$4B in potential peak revenue across enzyme, Pompe, GCase, Gaucher and FTD-GRN programs.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Denali Therapeutics